65. 原発性免疫不全症候群 Primary immunodeficiency Clinical trials / Disease details

臨床試験数 : 500 / 薬物数 : 614 - (DrugBank : 119) / 標的遺伝子数 : 92 - 標的パスウェイ数 : 217

2 trials found

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01946906 (ClinicalTrials.gov)	October 2013	12/9/2013	The Rifaximin Study in CVID	Effects of Rifaximin, by Modulation of the Gut Microbiota, on Markers of Systemic Inflammation in Pa ...	Common Variable Immunodeficiency (CVID)	Drug: Rifaximin	Oslo University Hospital	NULL	Completed	18 Years	74 Years	Both	40	Phase 4	Norway
2	EUCTR2013-000883-27-NO (EUCTR)	16/08/2013	20/06/2013	The effects of the local acting antibiotic Rifaximinon markers of inflammation in the blood by chang ...	EFFECTS OF RIFAXIMIN, BY MODULATION OF THE GUT MICROBIOTA, ON MARKERS OF SYSTEMIC INFLAMMATION IN PA ...	Adult patients with the diagnosis of Common variable deficiency and fulfill the inclusion and exclus ...	Trade Name: Xifaxan	Oslo University hospital	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Norway

First Previous1Next Last